[Post-transcriptional regulation mechanism and antiviral strategy of hepatitis B virus RNA].

D Y Li, D J Lu, C X Qu, T Zhang, J Liu, F M Lu, X M Chen
{"title":"[Post-transcriptional regulation mechanism and antiviral strategy of hepatitis B virus RNA].","authors":"D Y Li, D J Lu, C X Qu, T Zhang, J Liu, F M Lu, X M Chen","doi":"10.3760/cma.j.cn501113-20240410-00191","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic hepatitis B virus (HBV) infection is one of the major public health issues of ongoing global concern. Due to inadequate understanding of the HBV life cycle, there is a lack of effective drugs to cure chronic hepatitis B. During HBV replication, covalently closed circular DNA (cccDNA) serves as the template for viral replication and can be transcribed to produce five viral RNAs of 3.5, 2.4, 2.1 kb and 0.7 kb in length, which are translated to produce HBeAg, core protein, polymerase (P) protein, HBsAg and HBx proteins, respectively. Among them, the 3.5 kb pregenomic RNA (pgRNA) is also the template for viral reverse transcription. Polymerase protein recognizes and binds to the capsid assembly signal on the pgRNA to initiate capsid assembly and reverse transcription. Recent studies have revealed that the processes of splicing, nuclear export, stability, translation, and pgRNA encapsidation of HBV RNAs are regulated by a post-transcriptional regulatory network within the host cell and depend on unique post-transcriptional regulatory elements in the HBV RNA structure. The aim of this review is to overview the post-transcriptional regulatory mechanisms of HBV RNA and their applications in the study of HBV antiviral therapeutics, with the aim of providing new ideas for the development of new drugs targeting HBV RNA.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 5","pages":"474-480"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20240410-00191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic hepatitis B virus (HBV) infection is one of the major public health issues of ongoing global concern. Due to inadequate understanding of the HBV life cycle, there is a lack of effective drugs to cure chronic hepatitis B. During HBV replication, covalently closed circular DNA (cccDNA) serves as the template for viral replication and can be transcribed to produce five viral RNAs of 3.5, 2.4, 2.1 kb and 0.7 kb in length, which are translated to produce HBeAg, core protein, polymerase (P) protein, HBsAg and HBx proteins, respectively. Among them, the 3.5 kb pregenomic RNA (pgRNA) is also the template for viral reverse transcription. Polymerase protein recognizes and binds to the capsid assembly signal on the pgRNA to initiate capsid assembly and reverse transcription. Recent studies have revealed that the processes of splicing, nuclear export, stability, translation, and pgRNA encapsidation of HBV RNAs are regulated by a post-transcriptional regulatory network within the host cell and depend on unique post-transcriptional regulatory elements in the HBV RNA structure. The aim of this review is to overview the post-transcriptional regulatory mechanisms of HBV RNA and their applications in the study of HBV antiviral therapeutics, with the aim of providing new ideas for the development of new drugs targeting HBV RNA.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[乙型肝炎病毒 RNA 的转录后调控机制和抗病毒策略]。
慢性乙型肝炎病毒(HBV)感染是全球持续关注的主要公共卫生问题之一。在 HBV 复制过程中,共价闭合环状 DNA(cccDNA)是病毒复制的模板,可转录产生长度为 3.5、2.4、2.1 kb 和 0.7 kb 的五种病毒 RNA,分别翻译产生 HBeAg、核心蛋白、聚合酶(P)蛋白、HBsAg 和 HBx 蛋白。其中,3.5 kb 的前基因组 RNA(pgRNA)也是病毒反转录的模板。聚合酶蛋白识别并结合 pgRNA 上的囊膜组装信号,启动囊膜组装和逆转录。最近的研究发现,HBV RNA 的剪接、核输出、稳定性、翻译和 pgRNA 封装过程受宿主细胞内转录后调控网络的调控,并依赖于 HBV RNA 结构中独特的转录后调控元件。本综述旨在概述 HBV RNA 的转录后调控机制及其在 HBV 抗病毒疗法研究中的应用,以期为开发针对 HBV RNA 的新药提供新思路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
中华肝脏病杂志
中华肝脏病杂志 Medicine-Medicine (all)
CiteScore
1.20
自引率
0.00%
发文量
7574
期刊介绍:
期刊最新文献
[The Research and Application Progress of Heterologous Liver Transplantation]. [The nomogram model and its value study of Gd-EOB-DTPA enhanced MRI for preoperative diagnosis of proliferative hepatocellular carcinoma]. [Excerpt from the 2023 European Association for the Study of the Liver practice guidelines: prevention, diagnosis, and treatment of intrahepatic cholangiocarcinoma]. [Rifaximin curative effect and mechanism on monocrotaline-induced hepatic sinusoidal obstruction syndrome in mice]. [A case of Wilson's disease misdiagnosed as autoimmune hepatitis and literature review].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1